| 1. |
- Allison, Robert S., et al.
(författare)
-
Perspectives on the definition of visually lossless quality for mobile and large format displays
- 2018
-
Ingår i: Journal of Electronic Imaging (JEI). - 1017-9909 .- 1560-229X. ; 27:5, s. 1-23
-
Tidskriftsartikel (refereegranskat)abstract
- Advances in imaging and display engineering have given rise to new and improved image and videoapplications that aim to maximize visual quality under given resource constraints (e.g., power, bandwidth).Because the human visual system is an imperfect sensor, the images/videos can be represented in a mathematicallylossy fashion but with enough fidelity that the losses are visually imperceptible—commonly termed“visually lossless.” Although a great deal of research has focused on gaining a better understanding ofthe limits of human vision when viewing natural images/video, a universally or even largely accepted definitionof visually lossless remains elusive. Differences in testing methodologies, research objectives, and targetapplications have led to multiple ad-hoc definitions that are often difficult to compare to or otherwise employ inother settings. We present a compendium of technical experiments relating to both vision science and visualquality testing that together explore the research and business perspectives of visually lossless image quality,as well as review recent scientific advances. Together, the studies presented in this paper suggest that a singledefinition of visually lossless quality might not be appropriate; rather, a better goal would be to establish varyinglevels of visually lossless quality that can be quantified in terms of the testing paradigm.
|
|
| 2. |
- Scott, James S., et al.
(författare)
-
Circumventing seizure activity in a series of G protein coupled receptor 119 (GPR119) agonists
- 2014
-
Ingår i: Journal of Medicinal Chemistry. - : American Chemical Society. - 0022-2623 .- 1520-4804. ; 57:21, s. 8984-8998
-
Tidskriftsartikel (refereegranskat)abstract
- Agonism of GPR119 is viewed as a potential therapeutic approach for the treatment of type II diabetes and other elements of metabolic syndrome. During progression of a previously disclosed candidate 1 through mice toxicity studies, we observed tonic-clonic convulsions in several mice at high doses. An in vitro hippocampal brain slice assay was used to assess the seizure liability of subsequent compounds, leading to the identification of an aryl sulfone as a replacement for the 3-cyano pyridyl group. Subsequent optimization to improve the overall profile, specifically with regard to hERG activity, led to alkyl sulfone 16. This compound did not cause tonic-clonic convulsions in mice, had a good pharmacokinetic profile, and displayed in vivo efficacy in murine models. Importantly, it was shown to be effective in wild-type (WT) but not GPR119 knockout (KO) animals, consistent with the pharmacology observed being due to agonism of GPR119.
|
|
